Bronchodilator Responsiveness to Formoterol (FM)-Containing Treatments by Chronic Obstructive Pulmonary Disease (COPD) Severity Classification

Data were pooled from common treatment arms in 2 randomized, double-blind, multicenter studies (I: 6-mo; NCT00206154 [Drugs. 2008;68:1975-2000]; II: 12-mo; NCT00206167 [Drugs. 2009;69:549-65]) in COPD patients >=40 y. Treatments: twice-daily budesonide/FM pressurized metered-dose inhaler (BUD/FM...

Full description

Saved in:
Bibliographic Details
Published inJournal of allergy and clinical immunology Vol. 125; no. 2; p. AB66
Main Authors Tashkin, D.P, Celli, B.R, Rennard, S.I, McElhattan, J, Martin, U.J
Format Journal Article
LanguageEnglish
Published St. Louis Mosby, Inc 01.02.2010
Elsevier Limited
Subjects
Allergy and Immunology
Asthma
Chronic obstructive pulmonary disease
Drug therapy
Emphysema
Online AccessGet full text

Cover

More Information
Summary:Data were pooled from common treatment arms in 2 randomized, double-blind, multicenter studies (I: 6-mo; NCT00206154 [Drugs. 2008;68:1975-2000]; II: 12-mo; NCT00206167 [Drugs. 2009;69:549-65]) in COPD patients >=40 y. Treatments: twice-daily budesonide/FM pressurized metered-dose inhaler (BUD/FM pMDI) 320/9 μg (n=101 [I]; n=121 [II]), BUD/FM pMDI 160/9 μg (n=102 [I]; n=121 [II]), FM dry powder inhaler 9 μg (n=104 [I]; n=124 [II]), placebo (n=108 [I]; n=125 [II]).
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2009.12.259